129 related articles for article (PubMed ID: 8080669)
21. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
[TBL] [Abstract][Full Text] [Related]
22. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer.
Anderson KS; Ramachandran N; Wong J; Raphael JV; Hainsworth E; Demirkan G; Cramer D; Aronzon D; Hodi FS; Harris L; Logvinenko T; LaBaer J
J Proteome Res; 2008 Apr; 7(4):1490-9. PubMed ID: 18311903
[TBL] [Abstract][Full Text] [Related]
23. Plasma Autoantibodies Associated with Basal-like Breast Cancers.
Wang J; Figueroa JD; Wallstrom G; Barker K; Park JG; Demirkan G; Lissowska J; Anderson KS; Qiu J; LaBaer J
Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1332-40. PubMed ID: 26070530
[TBL] [Abstract][Full Text] [Related]
24. [Serum p53 antibody assay: evaluation in colorectal cancer].
Hammel P; Soussi T
Rev Med Interne; 2000 Feb; 21(2):167-73. PubMed ID: 10703073
[TBL] [Abstract][Full Text] [Related]
25. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
26. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue.
Wild CP; Ridanpää M; Anttila S; Lubin R; Soussi T; Husgafvel-Pursiainen K; Vainio H
Int J Cancer; 1995 Jun; 64(3):176-81. PubMed ID: 7622306
[TBL] [Abstract][Full Text] [Related]
27. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
Looi K; Megliorino R; Shi FD; Peng XX; Chen Y; Zhang JY
Oncol Rep; 2006 Nov; 16(5):1105-10. PubMed ID: 17016600
[TBL] [Abstract][Full Text] [Related]
28. Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma.
Ryder SD; Rizzi PM; Volkmann M; Metivier E; Pereira LM; Galle PR; Naoumov NV; Zentgraf H; Williams R
J Clin Pathol; 1996 Apr; 49(4):295-9. PubMed ID: 8655704
[TBL] [Abstract][Full Text] [Related]
29. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases.
Laurent-Puig P; Lubin R; Semhoun-Ducloux S; Pelletier G; Fourre C; Ducreux M; Briantais MJ; Buffet C; Soussi T
Gut; 1995 Mar; 36(3):455-8. PubMed ID: 7698709
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
[TBL] [Abstract][Full Text] [Related]
31. Autoantibodies response to MDM2 and p53 in the immunodiagnosis of esophageal squamous cell carcinoma.
Chai Y; Peng B; Dai L; Qian W; Zhang Y; Zhang JY
Scand J Immunol; 2014 Nov; 80(5):362-8. PubMed ID: 24965442
[TBL] [Abstract][Full Text] [Related]
32. Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance.
Würl P; Weigmann F; Meye A; Fittkau M; Rose U; Berger D; Rath FW; Dralle H; Taubert H
Scand J Gastroenterol; 1997 Nov; 32(11):1147-51. PubMed ID: 9399397
[TBL] [Abstract][Full Text] [Related]
33. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
[TBL] [Abstract][Full Text] [Related]
34. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.
Lechpammer M; Lukac J; Lechpammer S; Kovacević D; Loda M; Kusić Z
Int J Colorectal Dis; 2004 Mar; 19(2):114-20. PubMed ID: 14634775
[TBL] [Abstract][Full Text] [Related]
35. Anti-p53 antibodies in serum of smokers and head and neck cancer patients.
Wollenberg B; Jan NV; Pitzke P; Reiter W; Stieber P
Anticancer Res; 1997; 17(1A):413-8. PubMed ID: 9066686
[TBL] [Abstract][Full Text] [Related]
36. The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Gao RJ; Bao HZ; Yang Q; Cong Q; Song JN; Wang L
Breast Cancer Res Treat; 2005 Sep; 93(2):111-5. PubMed ID: 16187230
[TBL] [Abstract][Full Text] [Related]
37. The circulating auto-antibodies to p53 protein in the follow-up of lymphoma patients.
Jezersek B; Rudolf Z; Novakovic S
Oncol Rep; 2001; 8(1):77-81. PubMed ID: 11115573
[TBL] [Abstract][Full Text] [Related]
38. Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer.
Suppiah A; Greenman J
World J Gastroenterol; 2013 Aug; 19(29):4651-70. PubMed ID: 23922463
[TBL] [Abstract][Full Text] [Related]
39. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.
Thorlacius S; Thorgilsson B; Björnsson J; Tryggvadottir L; Börresen AL; Ogmundsdottir HM; Eyfjörd JE
Eur J Cancer; 1995 Oct; 31A(11):1856-61. PubMed ID: 8541113
[TBL] [Abstract][Full Text] [Related]
40. [Serum anti-p53 antibodies in gastric cancer patients].
Lawniczak M; Bielicki D; Sulzyc-Bielicka V; Marlicz K; Starzyńska T
Pol Merkur Lekarski; 2007 Sep; 23(135):192-5. PubMed ID: 18080693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
